Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Armour Pharmaceutical published information about the current state of knowledge regarding non-A non-B Hepatitis.

  • Read more about Armour Pharmaceutical published information about the current state of knowledge regarding non-A non-B Hepatitis.

Professor Zuckerman concluded that the use of blood concentrates should be restricted to life-threatening situations until blood donors could be screened for non-A non-B Hepatitis.

  • Read more about Professor Zuckerman concluded that the use of blood concentrates should be restricted to life-threatening situations until blood donors could be screened for non-A non-B Hepatitis.

An article in The Lancet expressed concerns about the long-term consequences of non-A non-B Hepatitis.

  • Read more about An article in The Lancet expressed concerns about the long-term consequences of non-A non-B Hepatitis.

Immuno considered that the British market would accept a higher risk of hepatitis for a lower-priced product.

  • Read more about Immuno considered that the British market would accept a higher risk of hepatitis for a lower-priced product.

Professor Ingram asked Professor Charles Rizza to update the UKHCDO meeting minutes regarding the Immuno products.

  • Read more about Professor Ingram asked Professor Charles Rizza to update the UKHCDO meeting minutes regarding the Immuno products.

It was raised at a UKHCDO meeting that Immuno would start selling Kryobulin Factor 8 concentrate at two prices.

  • Read more about It was raised at a UKHCDO meeting that Immuno would start selling Kryobulin Factor 8 concentrate at two prices.

Dr Garrott Allen found that prison blood accounted for 90% of post-transfusion icteric hepatitis.

  • Read more about Dr Garrott Allen found that prison blood accounted for 90% of post-transfusion icteric hepatitis.

Dr Rosemary Biggs predicted that within the next two years very large amounts of commercial products would become available in the US, and the UK would be obliged to purchase them at a high cost if it did not make urgent plans to meet its domestic demand.

  • Read more about Dr Rosemary Biggs predicted that within the next two years very large amounts of commercial products would become available in the US, and the UK would be obliged to purchase them at a high cost if it did not make urgent plans to meet its domestic demand.

The NHS advisory report on testing for Hepatitis B described the methods available for detecting HBsAg and anti-HBs and recommended that CIE should no longer be used and that regional transfusion centres should use either reverse passive haemagglutination or radioimmunoassay.

  • Read more about The NHS advisory report on testing for Hepatitis B described the methods available for detecting HBsAg and anti-HBs and recommended that CIE should no longer be used and that regional transfusion centres should use either reverse passive haemagglutination or radioimmunoassay.

A World Health Organization Scientific Group report on viral hepatitis stated that the present techniques for detecting Hepatitis B antigen were thought capable of preventing up to 30% of post-transfusion hepatitis, which were deemed more sensitive than earlier techniques.

  • Read more about A World Health Organization Scientific Group report on viral hepatitis stated that the present techniques for detecting Hepatitis B antigen were thought capable of preventing up to 30% of post-transfusion hepatitis, which were deemed more sensitive than earlier techniques.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 466
  • Page 467
  • Page 468
  • Page 469
  • Current page 470
  • Page 471
  • Page 472
  • Page 473
  • Page 474
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.